Market research
000627.SHE Hubei Biocause Pharmaceutical Co., Ltd
SHE CNY Financial Services
Latest close
—
—
Loading market data…
Test a moving-average rule with historical data.
Market facts
- Market cap
- 8B
- P/E ratio
- Not available
- Analyst target
- Not available
- Dividend yield
- Not available
- Beta
- 0.68
Community
Investor discussion
1 comment
Sign in to join the 000627.SHE discussion.
5 years, 5 months ago
Hubei Biocause Pharmaceutical Co., Ltd is currently in a long term downtrend where the price is trading 17.2% below its 200 day moving average.
From a valuation standpoint, the stock is 84.4% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 1.5.
Hubei Biocause Pharmaceutical Co., Ltd's total revenue rose by 26.1% to $3B since the same quarter in the previous year.
Its net income has dropped by 79.4% to $55M since the same quarter in the previous year.
Finally, its free cash flow grew by 12.7% to $4B since the same quarter in the previous year.
Based on the above factors, Hubei Biocause Pharmaceutical Co., Ltd gets an overall score of 3/5.